Hisham Abdel-Azim MD MS; ASH 2025: Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Busting Brain Myths: TikTok's Viral Neuroscientist 11 min · 24 Sep 2026 · Today with David McCullagh

We Investigated the Christian "Scam" Fronted by Tim Tebow 1h 17m · 24 Sep 2026 · Pablo Torre Finds Out

Trump threatens Iran in fiery UN speech. What's next? 14 min · 24 Sep 2026 · The Excerpt

Why Grit Isn’t Always Enough with Angela Duckworth 1h 3m · 24 Sep 2026 · The Curiosity Shop with Brené Brown and Adam Grant

Trump Wakes Up to Nightmare With Xi 17 min · 24 Sep 2026 · The MeidasTouch Podcast

Stress: The Science of Chilling Out 37 min · 24 Sep 2026 · Science Vs

Report any issue

Source

Recorded06 Jan 2026

Publisheraudiomedica.com ↗

Handlerec:19315695

Show notes

Dr. Hisham Abdel-Azim discusses findings from the phase two EndRAD trial, presented at ASH 2025. The study reveals that Next Generation Sequencing-Assessed Minimum Residual Disease (NGS-MRD) can identify young patients with high-risk/relapsed B-cell Acute Lymphoblastic Lymphomas (B-ALL) who can safely omit pre-transplant Total Body Irradiation (TBI). This approach achieved comparable survival outcomes while potentially reducing TBI-associated late effects.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in